| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
181.65(B) |
| Last
Volume: |
2,611,876 |
Avg
Vol: |
2,730,756 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
4,213 |
23,771 |
32,103 |
| Total Sell Value |
$662,802 |
$1,235,078 |
$6,471,520 |
$8,588,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
2 |
4 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Santos Esteban |
EVP, Operations |
• • – |
2020-05-03 |
4 |
D |
$230.98 |
$44,810 |
D/D |
(194) |
43,049 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$29,424 |
D/D |
(123) |
41,640 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$80,139 |
D/D |
(335) |
29,307 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$27,510 |
D/D |
(115) |
24,202 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$654,745 |
D/D |
(2,737) |
534,541 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$250,224 |
D/D |
(1,046) |
38,124 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$131,332 |
D/D |
(549) |
47,911 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2020-05-01 |
4 |
D |
$239.22 |
$141,857 |
D/D |
(593) |
43,243 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$39,695 |
D/D |
(168) |
39,170 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$24,101 |
D/D |
(102) |
24,317 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$27,408 |
D/D |
(116) |
41,763 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$124,283 |
D/D |
(526) |
43,836 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$129,481 |
D/D |
(548) |
48,460 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$600,860 |
D/D |
(2,543) |
537,278 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2020-04-27 |
4 |
D |
$236.28 |
$79,154 |
D/D |
(335) |
29,642 |
|
- |
|
| Sugar Ronald D |
Director |
• • – |
2020-04-22 |
4 |
AS |
$233.35 |
$233,350 |
D/D |
(1,000) |
14,636 |
|
9% |
|
| Sugar Ronald D |
Director |
• • – |
2020-04-22 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
15,636 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2020-04-13 |
4 |
D |
$218.21 |
$18,374,591 |
D/D |
(84,206) |
539,821 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2020-04-13 |
4 |
OE |
$58.43 |
$7,420,610 |
D/D |
127,000 |
595,516 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$5,529,106 |
D/D |
(27,818) |
497,027 |
|
- |
|
| Johnston Lori A |
EVP, HR |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$737,201 |
D/D |
(3,709) |
29,977 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$1,284,983 |
D/D |
(6,465) |
44,362 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$1,152,013 |
D/D |
(5,796) |
49,008 |
|
- |
|
| Piacquad David |
SVP, Business Development |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$316,227 |
D/D |
(1,591) |
41,879 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2020-03-20 |
4 |
D |
$198.76 |
$368,700 |
D/D |
(1,855) |
39,338 |
|
- |
|
2195 Records found
|
|
Page 17 of 88 |
|
|
2.71 (0.87%) 
